Unlock Viral Vector Yield And Efficiency With Upstream Intensification

Viral vectors continue to lead the way in transformative therapies for gene therapy, vaccines, and cancer treatment. Yet, the industry faces significant hurdles due to inefficient and costly manufacturing processes that limit market supply and patient access. As the scope of viral vector applications expands to address a wider range of diseases, the need for improved production methods becomes increasingly urgent. One promising advancement is the use of perfusion technologies, which offer streamlined manufacturing, reduced cost of goods sold (COGS), and greater flexibility in scaling processes. Repligen’s tangential flow depth filtration (TFDF) process intensification system exemplifies this innovation to enable high cell density growth, perfusion-based vector production, and efficient harvest.

To stay ahead in the evolving landscape of viral vector therapeutics, explore how Repligen’s TFDF system can elevate your manufacturing strategy.